Matsuda T
Kanazawa University School of Medicine, Department of Internal Medicine (III).
Nihon Rinsho. 1998 Oct;56(10):2577-81.
Thrombolytic therapy in patients with acute coronary syndrome is not so widely used compared to coronary intervention, such as PTCA or stenting in Japan. This is probably because of the facts that the narrowing of the coronary artery is not completely restored after the thrombolytic therapy and that the coronary intervention is frequently necessary inspite of the administration of the thrombolytic agent. However, the thrombolytic therapy can be easily done in the peracute stage of myocardial infarction, and improvement of the prognosis of the affected patient may be possible. In this paper, the concepts as well as the effect of thrombolytic therapy and the characteristics of newly developed thrombolytic drugs are discussed.
与冠状动脉介入治疗(如日本的经皮冠状动脉腔内血管成形术(PTCA)或支架置入术)相比,急性冠状动脉综合征患者的溶栓治疗在日本并未得到如此广泛的应用。这可能是由于以下事实:溶栓治疗后冠状动脉狭窄并未完全恢复,而且尽管使用了溶栓剂,但仍经常需要进行冠状动脉介入治疗。然而,溶栓治疗在心肌梗死的超急性期很容易实施,并且可能改善受影响患者的预后。本文讨论了溶栓治疗的概念、效果以及新开发的溶栓药物的特点。